Bio-Product of the Day [23/06/2020]

ZMapp®
(Monocloanl Antibody)Â
–First drug of Ebola virus.
-Developed by Mapp Biopharmaceutical, Inc. and LeafBio, Inc.(San Diego, CA, USA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).
– First used on humans during the West Africa Ebola virus outbreak(2014).
–  FDA approved and granted it fast track status.
–Â Produced by Recombinant DNA
  Technology(RDT).
-Developed in the tobacco plant Nicotiana benthamiana.
-So it is categorized in the plantibody(plant derived antibody).
–Â It is a drug cocktail of three humanized monoclonal antibodies(MAbs; c2G4, c4G7, and c13C6).
-ZMapp  binds to three different epitopes on Ebola surface glycoprotein (GP).
References:Â
1. Tran EE, Nelson EA, Bonagiri P, et al. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. J Virol. 2016;90(17):7618-7627. Published 2016 Aug 12. doi:10.1128/JVI.00406-16
2. “ZMappâ„¢ is Granted Fast Track Status by the FDA”, September 17, 2015 – SAN DIEGO, url- https://mappbio.com/zmapp-is-granted-fast-track-status-by-the-fda/